Developed at Warwick University, the new method uses two so-called parent nanoparticles that are designed to interact only when in proximity to each other and trigger the release of drug molecules contained within both.
The release of the drug molecules from the parent nanoparticles could subsequently form what Warwick calls a third ‘daughter’ particle, which comprises molecules from both ‘parent’ nanoparticles.
The researchers, led by Professors Andrew Dove and Rachel O’Reilly, suggest that this new mechanism could potentially limit side-effects by only releasing the drug where required:
‘We conceive that in the blood stream the particles would not be able to interact sufficiently to lead to release, only when they are taken into cells would the release be able to happen’, Prof Dove said in a statement. ‘In this way, the drug can be targeted to only release where we want it to and therefore be more effective and reduce side effects’.
The chemical composition of the two parent nanoparticles is said to be crucial to the new method.
Prof Dove said: ‘The two ‘parent’ nanoparticles used in the new mechanism are cylindrical in shape and are made from polymer chains that differ only by the way in which chemical bonds are directed within a part of the structure.
‘When the two ‘parent’ nanoparticles are in close enough proximity the polymer chains are driven to come together to form a new ‘daughter’ nanoparticle by a phenomenon known as stereocomplexation.
‘In the process of this rearrangement, we propose that any molecules, such as drug molecules, that are encapsulated within the parent particles will be released.’
Published in journal Nature Communications the research, Structural reorganisation of cylindrical nanoparticles triggered by polylactide stereocomplexation, could raise new possibilities in how medical treatments are administered, said Prof Dove.
‘We’re planning to study this as a new treatment for cancer but the principle could potentially be applied to a wide range of diseases,’ he said.
Oxa launches autonomous Ford E-Transit for van and minibus modes
I'd like to know where these are operating in the UK. The report is notably light on this. I wonder why?